Liver toxicity is the number one reason for drugs to be retracted from the market. More reliable methods for predicting drug- induced liver toxicity will not only save drug development costs by detecting liver toxic drugs earlier, but will also spare patients from potential severe side effects due to liver toxicity.

On May 22, our General Director Bernard Mulder had the honor of joining His Majesty King Willem-Alexander of the Kingdom of the Netherlands, Prof. Yoshiki Sawa, Chairman of the Organization for Advanced Healthcare Innovation (Nakanoshima Qross), and H.E. Ms. Reinette Klever, Minister for Foreign Trade and Development Cooperation of the Netherlands.

We’re proud to share Frank Luyten his reflections in this original column, published by FAST and republished here by RegMed XB with permission.